Abstract
Leishmaniasis belongs to a group of neglected tropical infectious diseases, characterized by low research investment and lack of interest from the pharmaceutical industry. These diseases are generally endemic in Global South countries, affecting low-income populations. In an attempt to mitigate the harm caused by the disease and the lack of promising treatments, fragment-based drug design…